BMS cancer med could earn $500M
Analysts are rubbing their hands over the FDA's approval of Ixempra, a Bristol-Myers Squibb breast cancer treatment, predicting $500 million in annual sales by 2010. The drug got the agency's nod as a stand-alone treatment for patients who've failed other chemotherapy and for use in tandem with Roche's Xeloda in patients whose cancer has spread. A treatment course of Ixempra is expected to cost $18,000 to $23,000.
- see the BMS release
- check out the report from The Star-Ledger
- read the article from PharmaTimes
Related Articles:
BMS pays $505M for Adnexus. Report
Better times ahead for BMS? Report
Cornelius get big payday for BMS temp job. Report
Read more on: Bristol-Myers Squibb
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends